![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1660684
¼¼Æ÷ ±â¹Ý ¾î¼¼ÀÌ ½ÃÀå º¸°í¼ : Á¦Ç° ¹× ¼ºñ½ºº°, ±â¼úº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°(2025-2033³â)Cell-based Assay Market Report by Product and Services, Technology, Application, End-User, and Region 2025-2033 |
¼¼Æ÷ ±â¹Ý ¾î¼¼ÀÌ ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â 241¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2033³â±îÁö ½ÃÀå ±Ô¸ð°¡ 452¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇϸç, 2025³âºÎÅÍ 2033³â±îÁö 6.88%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» ±â·ÏÇÒ °ÍÀ¸·Î Àü¸ÁÇϰí ÀÖ½À´Ï´Ù. ´Ù¾çÇÑ Áúº´¿¡ ´ëÀÀÇϱâ À§ÇÑ »õ·Î¿î Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡, ¾à¹° ½ºÅ©¸®´×ÀÇ Á¤È®¼ºÀ» Çâ»ó½Ã۱â À§ÇÑ ¼¼Æ÷¹è¾ç ±â¼úÀÇ Çõ½Å µîÀÌ ½ÃÀåÀ» À̲ô´Â ÁÖ¿ä ¿äÀÎ Áß ÀϺÎÀÔ´Ï´Ù.
¼¼Æ÷ ±â¹Ý ¾î¼¼ÀÌ(¼¼Æ÷ ¾î¼¼À̶ó°íµµ ÇÔ)Àº ƯÁ¤ ¹°ÁúÀ̳ª Á¶°Ç¿¡ ¹ÝÀÀÇÏ´Â ¼¼Æ÷ÀÇ »ý¹°ÇÐÀû Ȱ¼ºÀ» Æò°¡Çϱâ À§ÇØ ´Ù¾çÇÑ °úÇÐ ¹× ÀÇ·á ºÐ¾ß¿¡¼ »ç¿ëµÇ´Â ½ÇÇè ±â¼úÀÔ´Ï´Ù. ÅëÁ¦µÈ ȯ°æ¿¡¼ »ì¾ÆÀÖ´Â ¼¼Æ÷¸¦ ¹è¾çÇÏ°í ¾à¹°, ÈÇÕ¹°, ȯ°æ ¿äÀÎ µî ´Ù¾çÇÑ Àڱؿ¡ ³ëÃâ½ÃŰ´Â °ÍÀ¸·Î ÀÌ·ç¾îÁý´Ï´Ù. ¼¼Æ÷ÀÇ »ýÁ¸À², ƯÁ¤ ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ¹ßÇö µî ¼¼Æ÷ÀÇ °Åµ¿ º¯È¸¦ ¸ð´ÏÅ͸µÇÔÀ¸·Î½á ¿¬±¸ÀÚµéÀº ½ÃÇè¹°ÁúÀÌ ¼¼Æ÷ ±â´É¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ Áß¿äÇÑ ÀλçÀÌÆ®¸¦ ¾òÀ» ¼ö Àֱ⠶§¹®¿¡ ¼¼Æ÷ ±â¹Ý ¾î¼¼ÀÌ¿¡ ´ëÇÑ ¼ö¿ä°¡ Àü ¼¼°èÀûÀ¸·Î Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
ÇöÀç, ½Å¾à °³¹ß, µ¶¼ºÇÐ ¿¬±¸, Áúº´ ¸ðµ¨¸µ, ¼¼Æ÷ ±âÀü ±Ô¸í µîÀ» À§ÇØ ¼¼Æ÷ ±â¹Ý ¾î¼¼ÀÌÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ´õºÒ¾î, Á¦¾à ÈÇÕ¹°ÀÇ ÀáÀçÀû È¿´É°ú ¾ÈÀü¼ºÀ» Æò°¡ÇϰíÀÚ ÇÏ´Â ¿ä±¸°¡ Áõ°¡ÇÏ¸é¼ ½ÃÀå ¼ºÀåÀ» °ÈÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿¬±¸ÀÚµéÀÌ ½ÃÀå °³¹ß Ãʱ⠴ܰ迡¼ ÀáÀçÀûÀÎ ºÎÀÛ¿ëÀ» ½Äº°Çϰí ÈÇÐÁ¦Ç°ÀÇ µ¶¼ºÀ» Æò°¡ÇÒ ¼ö ÀÖ´Â ¼¼Æ÷ ±â¹Ý ¾î¼¼ÀÌ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. À̿ʹ º°µµ·Î ¾Ï, ´ç´¢º´, ÀÚ°¡¸é¿ªÁúȯ°ú °°Àº ¸¸¼ºÁúȯÀÌ Àü ¼¼°èÀûÀ¸·Î Áõ°¡Çϰí ÀÖ´Â °Íµµ ¾÷°è ÅõÀÚÀڵ鿡°Ô À¯¸®ÇÑ ¼ºÀå ±âȸ¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÈÇÐÁ¦Ç°°ú ¿À¿° ¹°ÁúÀÌ ½Ä¹°°ú ¼ö»ý ½Ã½ºÅÛ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÒ Çʿ伺ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
´Ù¾çÇÑ Áúº´À» Ä¡·áÇÒ ¼ö ÀÖ´Â »õ·Î¿î Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
½Å¾à °³¹ß ¹× ¾à¹° °³¹ß¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼ Àü ¼¼°è °³ÀÎÀÇ ´Ù¾çÇÑ ¸¸¼ºÁúȯÀ» Ä¡·áÇÒ ¼ö ÀÖ´Â »õ·Î¿î Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¸é¼ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼¼Æ÷ ±â¹Ý ¾î¼¼À̸¦ ÅëÇØ ¿¬±¸ÀÚµéÀº ¼ö¸¹Àº ÀáÀçÀû ¾à¹° Èĺ¸¹°ÁúÀ» ½Å¼ÓÇϰí È¿À²ÀûÀ¸·Î ½ºÅ©¸®´×ÇÏ°í Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¼¼Æ÷¸¦ ´Ù¾çÇÑ ÈÇÕ¹°¿¡ ³ëÃâ½ÃÅ´À¸·Î½á °úÇÐÀÚµéÀº À¯È¿¼º ¹× ¾ÈÀü¼º ÇÁ·ÎÆÄÀϰú °°Àº ¼¼Æ÷ÀÇ Çൿ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. À̿ʹ º°µµ·Î, ¾à¹°ÀÌ Æ¯Á¤ ¼¼Æ÷ °æ·Î¿Í »óÈ£ ÀÛ¿ëÇÏ´Â ¹æ½ÄÀ» ±íÀÌ ÀÌÇØÇØ¾ß ÇÏ´Â Á¤¹Ð ÀÇÇп¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ ºÐ¼®Àº °³º° ȯÀÚÀÇ ÇÁ·ÎÇÊ¿¡ ¸Â°Ô ¾à¹° Ä¡·á¸¦ Á¶Á¤ÇÒ ¼ö ÀÖ´Â Ç÷§ÆûÀ» Á¦°øÇÕ´Ï´Ù.
¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡
¸ÂÃãÇü ÀǾàǰ¿¡ ´ëÇÑ ´ëÁßÀÇ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼ ½ÃÀå ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó ÀÇ·á ±â°üµéÀº °³º° ȯÀÚÀÇ À¯ÀüÀû, ºÐÀÚÀû, ¼¼Æ÷Àû Ư¼º¿¡ ¸Â´Â ¸ÂÃãÇü Ä¡·á ¼Ö·ç¼Ç¿¡ ºü¸£°Ô ÁÖ¸ñÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ´õºÒ¾î, ¼¼Æ÷ ±â¹Ý ¾î¼¼À̸¦ ÅëÇØ ¿¬±¸ÀÚµéÀº ´Ù¾çÇÑ ¾à¹° ¹× Ä¡·á¿¡ ´ëÇÑ È¯ÀÚ À¯·¡ ¼¼Æ÷ÀÇ ¹ÝÀÀÀ» Æò°¡ÇÏ¿© ÀáÀçÀûÀÎ ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈÇÏ¸é¼ °¡Àå È¿°úÀûÀÎ Ä¡·á¹ýÀ» ã¾Æ³¾ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸ÂÃãÇü ÀÇ·á´Â Ä¡·á °á°ú¸¦ °³¼±ÇÒ »Ó¸¸ ¾Æ´Ï¶ó ºñÈ¿À²ÀûÀÎ Ä¡·á¸¦ ÇÇÇÔÀ¸·Î½á ÀÇ·á ºñ¿ëÀ» Àý°¨ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±× °á°ú, ÀÓ»ó°ú ¿¬±¸ ¸ðµÎ¿¡¼ ¼¼Æ÷ ±â¹Ý ¾î¼¼ÀÌÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¼¼Æ÷ ±â¹Ý ¾î¼¼ÀÌ´Â ÀÇ·á °³ÀÔÀ» ȯÀÚÀÇ Æ¯Á¤ ¿ä±¸¿¡ ¸Â°Ô Á¶Á¤ÇÒ ¼ö ÀÖ´Â °·ÂÇÑ µµ±¸À̱⠶§¹®ÀÔ´Ï´Ù.
¼¼Æ÷¹è¾ç ±â¼ú Çõ½Å
¼¼Æ÷¹è¾ç ±â¼úÀÇ ¹ßÀüÀº ¼¼Æ÷ ±â¹Ý ¾î¼¼ÀÌÀÇ ´É·ÂÀ» Çâ»ó½Ã۰í ÀÖÀ¸¸ç, 3D ¹è¾ç ¹× ¿À°¡³ëÀ̵å´Â ¿¬±¸ÀÚµéÀÌ ÀÎü¿¡ ´õ °¡±î¿î ¼¼Æ÷ °Åµ¿À» ¿¬±¸ÇÏ°í ¾à¹° ½ºÅ©¸®´× ¹× µ¶¼º Å×½ºÆ®ÀÇ Á¤È®¼ºÀ» Çâ»ó½Ãų ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸¶ÀÌÅ©·ÎÇ÷çÀ̵å¿Í ·¦¿ÂĨ ±â¼úÀº ¼ÒÇüÈ ¹× ÀÚµ¿ÈµÈ ¼¼Æ÷ ±â¹Ý ¾î¼¼À̹ýÀ» °³¹ßÇÒ ¼ö ÀÖ°Ô ÇÏ¿© ½Å¾à °³¹ßÀÇ Ã³¸®·® ¹× È¿À²¼ºÀ» Çâ»ó½ÃŰ´Â µ¥ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó, ÀÌ·¯ÇÑ Ã·´Ü ¼¼Æ÷¹è¾ç ±â¼úÀ» ¼¼Æ÷ ±â¹Ý ¾î¼¼ÀÌ¿¡ ÅëÇÕÇÔÀ¸·Î½á ±× ¿¬°ü¼º°ú Àû¿ë¼ºÀ» ³ôÀÏ ¼ö ÀÖÀ¸¸ç, Áúº´ ¸ÞÄ¿´ÏÁòÀ» ±Ô¸íÇÏ°í º¸´Ù Á¤¹ÐÇÑ ÀǾàǰ Èĺ¸¹°Áú Æò°¡¿¡ ÀûÇÕÇÑ µµ±¸°¡ µÉ ¼ö ÀÖ½À´Ï´Ù.
The global cell-based assay market size reached USD 24.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 45.2 Billion by 2033, exhibiting a growth rate (CAGR) of 6.88% during 2025-2033. The growing demand for novel therapies to address various diseases, rising focus on personalized medicines, and innovations in cell culture technologies to improve the accuracy of drug screening are some of the major factors propelling the market.
A cell-based assay, also known as a cellular assay, is a laboratory technique that is used in various scientific and medical fields to assess the biological activity of cells in response to specific substances or conditions. It comprises culturing living cells in controlled environments and exposing them to various stimuli, such as drugs, compounds, or environmental factors. As it allows researchers to gain critical insights into the effects of the tested substances on cellular function by monitoring changes in cell behavior, such as cell viability or the expression of specific biomarkers, the demand for cell-based assay is increasing worldwide.
At present, the rising adoption of cell-based assays for drug discovery, toxicology studies, disease modeling, and understanding cellular mechanisms is supporting the growth of the market. Besides this, the increasing need to evaluate the potential efficacy and safety of pharmaceutical compounds is strengthening the growth of the market. Additionally, the growing demand for cell-based assays, as they enable researchers to identify potential adverse effects early in the development process and assess the toxicity of chemicals, is positively influencing the market. Apart from this, increasing incidences of numerous chronic diseases, such as cancer, diabetes, and autoimmune disorders, among individuals around the world are offering lucrative growth opportunities to industry investors. Furthermore, the rising need to assess the impact of chemicals and pollutants on plant and aquatic systems is bolstering the growth of the market.
Rising demand for novel therapies to address various diseases
The rising focus on drug discovery and development, along with the increasing demand for novel therapies to address various chronic diseases among individuals across the globe, is contributing to the growth of the market. In addition, cell-based assays enable researchers to screen and evaluate a vast number of potential drug candidates quickly and efficiently. By exposing cells to different compounds, scientists can assess their impact on cellular behavior, including their efficacy and safety profiles. Apart from this, there is an increase in the focus on precision medicine that necessitates a deep understanding of how drugs interact with specific cellular pathways. Moreover, these assays provide a platform for tailoring drug treatments to individual patient profiles.
Increasing focus on personalized medicines
The rising focus on personalized medicines among the masses is supporting the growth of the market. In line with this, healthcare facilities are rapidly focusing on treatment solutions that are customized to suit the genetic, molecular, and cellular characteristics of individual patients. Besides this, cell-based assays allow researchers to evaluate the response of patient-derived cells to various drugs and treatments and enable the identification of the most effective therapies while minimizing potential side effects. In addition, personalized medicine not only improves treatment outcomes but also reduces healthcare costs by avoiding ineffective treatments. As a result, there is an increase in the adoption of cell-based assays in both clinical and research settings, as they provide a powerful tool for tailoring medical interventions to the specific needs of patients.
Innovations in cell culture technologies
Advancements in cell culture techniques are enhancing the capabilities of cell-based assays. 3D cultures and organoids allow researchers to study cell behavior closer to the human body to improve the accuracy of drug screening and toxicity testing, which is offering a positive market outlook. Additionally, microfluidics and lab-on-a-chip technologies enable the development of miniaturized and automated cell-based assays that assist in increasing throughput and efficiency in drug discovery. In line with this, the integration of these advanced cell culture technologies into cell-based assays aids in enhancing their relevance and applicability, which makes them suitable tools for understanding disease mechanisms and evaluating drug candidates with greater precision.
Consumables represent the largest market segment
High-throughput screening accounts for the majority of the market share
Drug discovery dominates the market share
Pharmaceutical and biotechnology companies hold the biggest market share
North America exhibits a clear dominance, accounting for the largest cell-based assay market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America held the biggest market share due to the increasing demand for advanced assay technologies and consumables. In addition, the rising development of novel cell-based assay techniques is bolstering the growth of the market in the region. Apart from this, the growing focus on drug safety is positively influencing the market. In line with this, stringent regulatory standards are propelling the growth of the market in the North America region.
Major players are developing innovative assay technologies, such as novel reagents, assay kits, and platforms. This involves creating more physiologically relevant cell models to improve assay sensitivity and enhance automation and data analysis capabilities. In line with this, companies are expanding their product portfolios to cater to a wide range of applications. This includes offering assays tailored for specific targets, pathways, or disease models, and developing specialized kits for toxicity testing and drug screening. Apart from this, key manufacturers are providing customized assay development services and are working closely with clients to tailor assays to their specific research needs, which is offering a positive market outlook.